Strong Track Record in Delivering Innovative Medicines

The IRBM team has an impressive productivity record having delivered 25 peptide or small molecule preclinical candidates over 9 years. These include the marketed drug Isentress™, the first-in-class HIV integrase inhibitor for the treatment of HIV/AIDS (awarded the Prix Galien USA 2008 Award for the Best Pharmaceutical Agent), Grazoprevir a pan-genotypic HCV protease inhibitor, approved in 2016 in combination with Elbasvir as Zapatier™ as first interferon-free therapy for HCV, and Niraparib, a PARP inhibitor antitumor agent currently in phase III of clinical development.

The team also made key contributions to the development of Zolinza (SAHA): first-in-class HDAC inhibitor for the treatment of cancer. The contributions of IRBM to these achievements are documented in over 800 peer-reviewed articles and 100 patents.